Perinatal Drug Abuse and Neonatal Drug Withdrawal: Multimedia

References

1. [Best Evidence] O'Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. Apr 2009;123(4):e614-21. [Medline].

2. Lester BM. The Maternal Lifestyles Study. Ann N Y Acad Sci. Jun 21 1998;846:296-305. [Medline].

3. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol. Feb 2003;101(2):374-9. [Medline].

4. Wilsnack SC, Beckman LJ. Drinking, sexuality, and sexual dysfunction in women. In: Alcohol Problems in Women: Antecedents, Consequences, and Intervention. New York, NY: Guilford Press; 1984:189.

5. Hien D, Scheier J. Trauma and short-term outcome for women in detoxification. J Subst Abuse Treat. May-Jun 1996;13(3):227-31. [Medline].

6. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. Nov 21 1990;264(19):2511-8. [Medline].

7. Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol. Aug 2003;189(2):312-7. [Medline].

8. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. Nov 2008;84(5):604-12. [Medline].

9. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. Sep 2008;122(3):e601-7. [Medline].

10. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. Jun 2008;6(2):125-50. [Medline].

11. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. Jul 2005;79(1):1-10. [Medline].

12. Stroud LR, Paster RL, Papandonatos GD, Niaura R, Salisbury AL, Battle C. Maternal smoking during pregnancy and newborn neurobehavior: effects at 10 to 27 days. J Pediatr. Jan 2009;154(1):10-6. [Medline].

13. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON. Jul 2005;(16):vii-III1. [Medline].

14. Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. Sep 2006;118(3):1149-56. [Medline].

15. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawalsyndrome: a database analysis. Lancet. Feb 5-11 2005;365(9458):482-7. [Medline].

16. Ryan RM, Wagner CL, Schultz JM, et al. Meconium analysis for improved identification of infants exposed to cocaine in utero. J Pediatr. Sep 1994;125(3):435-40. [Medline].

17. Finnegan LP. Neonatal abstinence syndrome: Assessment and pharmacotherapy. In: In Neonatal Therapy: An Update. 1986:122-46.

18. Coyle MG, Ferguson A, Lagasse L, et al. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatalopiate withdrawal in term infants. J Pediatr. May 2002;140(5):561-4. [Medline].

19. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. Jun 2006;117(6):e1163-9. [Medline].

20. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. Jan 2008;121(1):106-14. [Medline].

21. Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol. Jan 2009;200(1):70.e1-5. [Medline].

22. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. Oct 2008;199(4):396.e1-7. [Medline].

23. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. Mar 16 2007;87(2-3):131-8. [Medline].

24. [Guideline] AAP. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs [published erratum appears in Pediatrics 1998 Sep;102(3 Pt 1):660]. Pediatrics. Jun 1998;101(6):1079-88. [Medline]. [Full Text].

25. Bauer CR. Perinatal effects of prenatal drug exposure. Neonatal aspects. Clin Perinatol. Mar 1999;26(1):87-106. [Medline].

26. Behnke M, Eyler FD, Warner TD, Garvan CW, Hou W, Wobie K. Outcome from a prospective, longitudinal study of prenatal cocaine use: preschool development at 3 years of age. J Pediatr Psychol. Jan-Feb 2006;31(1):41-9. [Medline].

27. Bishai R, Koren G. Maternal and obstetric effects of prenatal drug exposure. Clin Perinatol. Mar 1999;26(1):75-86, vii. [Medline].

28. Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by levelof prenatal tobacco exposure. Drug Alcohol Depend. Sep 6 2004;75(3):253-60. [Medline].

29. Coyle MG, Ferguson A, Lagasse L, et al. Neurobehavioral effects of treatment for opiate withdrawal. Arch Dis Child Fetal Neonatal Ed. Jan 2005;90(1):F73-4. [Medline].

30. Eyler FD, Behnke M. Early development of infants exposed to drugs prenatally. Clin Perinatol. Mar 1999;26(1):107-50, vii. [Medline].

31. Flanagan P, Kokotailo P. Adolescent pregnancy and substance use. Clin Perinatol. Mar 1999;26(1):185-200. [Medline].

32. Gewolb IH, Fishman D, Qureshi MA, Vice FL. Coordination of suck-swallow-respiration in infants born to mothers with drug-abuseproblems. Dev Med Child Neurol. Oct 2004;46(10):700-5. [Medline].

33. Hans SL. Demographic and psychosocial characteristics of substance-abusing pregnant women. Clin Perinatol. Mar 1999;26(1):55-74. [Medline].

34. Hoyme HE, May PA, Kalberg WO, et al. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine criteria. Pediatrics. Jan 2005;115(1):39-47. [Medline].

35. Jackson L, Ting A, McKay S, et al. A randomised controlled trial of morphine versus phenobarbitone for neonatalabstinence syndrome. Arch Dis Child Fetal Neonatal Ed. Jul 2004;89(4):F300-4. [Medline].

36. Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. Jul 2004;89(4):F300-4. [Medline].

37. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. Jan 2003;88(1):F2-5. [Medline].

38. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. Jan 2003;88(1):F2-5. [Medline].

39. Kosofsky BE. Cocaine-Induced Alterations in Neuro-Development. Seminars in Speech and language. 1998;19(2):109-121. [Medline].

40. Kuschel CA, Austerberry L, Cornwell M, et al. Can methadone concentrations predict the severity of withdrawal in infantsat risk of neonatal abstinence syndrome?. Arch Dis Child Fetal Neonatal Ed. Sep 2004;89(5):F390-3. [Medline].

41. Langenfeld S, Birkenfeld L, Herkenrath P, et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphinedrops. Drug Alcohol Depend. Jan 7 2005;77(1):31-6. [Medline].

42. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. Sep 2005;193(3 Pt 1):606-10. [Medline].

43. Messinger DS, Bauer CR, Das A, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics. Jun 2004;113(6):1677-85. [Medline].

44. [Best Evidence] Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005;(3):CD002059. [Medline].

45. [Best Evidence] Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005;CD002059. [Medline].

46. [Best Evidence] Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005;CD002053. [Medline].

47. Philipp BL, Merewood A, O'Brien S. Methadone and breastfeeding: new horizons. Pediatrics. Jun 2003;111(6 Pt 1):1429-30. [Medline]. [Full Text].

48. Shephard R, Greenough A, Johnson K, Gerada C. Hyperphagia, weight gain and neonatal drug withdrawal. Acta Paediatr. 2002;91(9):951-3. [Medline].

49. Smeriglio VL. Prenatal Drug Exposure and Child Outcome. Clinics in Perinatology. 1999;26(1):1-15. [Medline].

50. Tan-Laxa MA, Sison-Switala C, Rintelman W, Ostrea EM Jr. Abnormal auditory brainstem response among infants with prenatal cocaine exposure. Pediatrics. Feb 2004;113(2):357-60. [Medline].

51. Tronick EZ, Beeghly M. Prenatal cocaine exposure, child development, and the compromising effects of cumulative risk. Clin Perinatol. Mar 1999;26(1):151-71. [Medline].

52. Vinner E, Vignau J, Thibault D, et al. Neonatal hair analysis contribution to establishing a gestational drug exposureprofile and predicting a withdrawal syndrome. Ther Drug Monit. Aug 2003;25(4):421-32. [Medline].

Further Reading

Keywords

perinatal drug abuse, neonatal drug withdrawal, neonatal abstinence syndrome, neonatal withdrawal syndrome, substance abuse during pregnancy, maternal drug abuse, opiates, cocaine, nicotine, alcohol, maternal drug abuse, newborn withdrawal syndrome, prematurity, heroin, codeine, methadone, meperidine, fetal alcohol syndrome, poor feeding, attention deficit hyperactivity disorder, ADHD, hyperphagia, diaphoresis, hyperacusis, apnea, tachycardia, alcohol-related neurodevelopmental disorder, ARND, low birth weight, fetal hypoxia

Contributor Information and Disclosures

Author

Marvin Wang, MD, Clinical Instructor, Department of Pediatrics, Harvard Medical School; Co-director of Newborn Nurseries, Attending Physician, Department of Pediatrics, Massachusetts General Hospital,
Disclosure: Nothing to disclose.

Medical Editor

David N Sheftel, MD, Director, Division of Neonatology, Clinical Associate Professor, Department of Pediatrics, Lutheran General Children's Hospital of Park Ridge, Chicago Medical School
David N Sheftel, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Pediatrics
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Brian S Carter, MD, FAAP, Professor of Pediatrics (Neonatology), Vanderbilt University School of Medicine; Co-director, Pediatric Advance Comfort Team, Monroe Carell Jr Children's Hospital at Vanderbilt
Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Society for Bioethics and Humanities, American Society of Law Medicine and Ethics, National Hospice and Palliative Care Organization, and Southern Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.